» Articles » PMID: 38139018

MELAS-Derived Neurons Functionally Improve by Mitochondrial Transfer from Highly Purified Mesenchymal Stem Cells (REC)

Abstract

Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episode (MELAS) syndrome, caused by a single base substitution in mitochondrial DNA (m.3243A>G), is one of the most common maternally inherited mitochondrial diseases accompanied by neuronal damage due to defects in the oxidative phosphorylation system. There is no established treatment. Our previous study reported a superior restoration of mitochondrial function and bioenergetics in mitochondria-deficient cells using highly purified mesenchymal stem cells (RECs). However, whether such exogenous mitochondrial donation occurs in mitochondrial disease models and whether it plays a role in the recovery of pathological neuronal functions is unknown. Here, utilizing induced pluripotent stem cells (iPSC), we differentiated neurons with impaired mitochondrial function from patients with MELAS. MELAS neurons and RECs/mesenchymal stem cells (MSCs) were cultured under contact or non-contact conditions. Both RECs and MSCs can donate mitochondria to MELAS neurons, but RECs are more excellent than MSCs for mitochondrial transfer in both systems. In addition, REC-mediated mitochondrial transfer significantly restored mitochondrial function, including mitochondrial membrane potential, ATP/ROS production, intracellular calcium storage, and oxygen consumption rate. Moreover, mitochondrial function was maintained for at least three weeks. Thus, REC-donated exogenous mitochondria might offer a potential therapeutic strategy for treating neurological dysfunction in MELAS.

Citing Articles

Mitochondrial diseases: from molecular mechanisms to therapeutic advances.

Wen H, Deng H, Li B, Chen J, Zhu J, Zhang X Signal Transduct Target Ther. 2025; 10(1):9.

PMID: 39788934 PMC: 11724432. DOI: 10.1038/s41392-024-02044-3.


Integrating Mitochondrial Biology into Innovative Cell Therapies for Neurodegenerative Diseases.

Ore A, Angelastro J, Giulivi C Brain Sci. 2024; 14(9).

PMID: 39335395 PMC: 11429837. DOI: 10.3390/brainsci14090899.

References
1.
Goto Y, Nonaka I, Horai S . A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature. 1990; 348(6302):651-3. DOI: 10.1038/348651a0. View

2.
Grady J, Pickett S, Ng Y, Alston C, Blakely E, Hardy S . mtDNA heteroplasmy level and copy number indicate disease burden in m.3243A>G mitochondrial disease. EMBO Mol Med. 2018; 10(6). PMC: 5991564. DOI: 10.15252/emmm.201708262. View

3.
Austefjord M, Gerdes H, Wang X . Tunneling nanotubes: Diversity in morphology and structure. Commun Integr Biol. 2014; 7(1):e27934. PMC: 3995728. DOI: 10.4161/cib.27934. View

4.
Klein Gunnewiek T, van Hugte E, Frega M, Guardia G, Foreman K, Panneman D . m.3243A > G-Induced Mitochondrial Dysfunction Impairs Human Neuronal Development and Reduces Neuronal Network Activity and Synchronicity. Cell Rep. 2020; 31(3):107538. DOI: 10.1016/j.celrep.2020.107538. View

5.
Wada K, Itoga K, Okano T, Yonemura S, Sasaki H . Hippo pathway regulation by cell morphology and stress fibers. Development. 2011; 138(18):3907-14. DOI: 10.1242/dev.070987. View